» Articles » PMID: 39313811

Fetal and Obstetrics Manifestations of Mitochondrial Diseases

Abstract

During embryonic and neonatal development, mitochondria have essential effects on metabolic and energetic regulation, shaping cell fate decisions and leading to significant short- and long-term effects on embryonic and offspring health. Therefore, perturbation on mitochondrial function can have a pathological effect on pregnancy. Several shreds of evidence collected in preclinical models revealed that severe mitochondrial dysfunction is incompatible with life or leads to critical developmental defects, highlighting the importance of correct mitochondrial function during embryo-fetal development. The mechanism impairing the correct development is unknown and may include a dysfunctional metabolic switch in differentiating cells due to decreased ATP production or altered apoptotic signalling. Given the central role of mitochondria in embryonic and fetal development, the mitochondrial dysfunction typical of Mitochondrial Diseases (MDs) should, in principle, be detectable during pregnancy. However, little is known about the clinical manifestations of MDs in embryonic and fetal development. In this manuscript, we review preclinical and clinical evidence suggesting that MDs may affect fetal development and highlight the fetal and maternal outcomes that may provide a wake-up call for targeted genetic diagnosis.

Citing Articles

FBXL4-Related Mitochondrial Depletion Syndrome Underscores the role of Mitophagy in Stem Cell Differentiation during Embryogenesis.

Prasun P Stem Cell Rev Rep. 2025; .

PMID: 39937392 DOI: 10.1007/s12015-025-10854-3.


Correction to: Fetal and obstetrics manifestations of mitochondrial diseases.

Adelizzi A, Giri A, Di Donfrancesco A, Boito S, Prigione A, Bottani E J Transl Med. 2024; 22(1):1110.

PMID: 39639348 PMC: 11619335. DOI: 10.1186/s12967-024-05862-9.

References
1.
Brunetti D, Dykstra W, Le S, Zink A, Prigione A . Mitochondria in neurogenesis: Implications for mitochondrial diseases. Stem Cells. 2021; 39(10):1289-1297. DOI: 10.1002/stem.3425. View

2.
Gorman G, Schaefer A, Ng Y, Gomez N, Blakely E, Alston C . Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015; 77(5):753-9. PMC: 4737121. DOI: 10.1002/ana.24362. View

3.
Poulton J, Finsterer J, Yu-Wai-Man P . Genetic Counselling for Maternally Inherited Mitochondrial Disorders. Mol Diagn Ther. 2017; 21(4):419-429. DOI: 10.1007/s40291-017-0279-7. View

4.
Bugiardini E, Bottani E, Marchet S, Poole O, Beninca C, Horga A . Expanding the molecular and phenotypic spectrum of truncating mutations. Neurol Genet. 2020; 6(1):e381. PMC: 6984135. DOI: 10.1212/NXG.0000000000000381. View

5.
Pitceathly R, Murphy S, Cottenie E, Chalasani A, Sweeney M, Woodward C . Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology. 2012; 79(11):1145-54. PMC: 3525307. DOI: 10.1212/WNL.0b013e3182698d8d. View